Arrowhead Pharmaceuticals, Inc. Financials

Market Capitalization $2.32 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	-3.36
Forward PE	-3.98
Price to Sales TTM	$4.25
Price to Book MRQ	$3.39
Enterprise to Revenue	3.35
Enterprise to EBITDA	-18.76

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-09-30
Most Recent Quarter	2025-03-31
Profit Margin	-26.41%
Operating Margin	70.24%
Return on Assets TTM	-5.86%
Return on Equity TTM	-26.22%

Income Statement

Revenue TTM	$545,209,024
Revenue per Share TTM	$4.31
Quarterly Revenue Growth	21608.36%
Gross Profit TTM	$545,209,024
EBITDA	$-97,428,000
Net Income to Common TTM	$-143,968,992
Diluted EPS TTM	$-1.24
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$1,095,309,056
Total Cash per Share MRQ	$7.93
Total Debt MRQ	$
Total Debt to Equity MRQ	108.23
Current Ratio MRQ	5.15
Book Value per Share MRQ	$4.95

Cash Flow

Operating Cash Flow TTM	$61,147,000
Levered Free Cash Flow TTM	$-6,458,500

ARWR Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	124,376,000
Float Shares	120,895,883
Avg 10 Volume	1,562,500
Avg 30 Volume	None
Shares Short	12,680,408
Short Ratio	6.95
Short % of Shares	11.85%
% Held by Insiders	13.02%
% Held by Institutions	77.19%

Stock Price Summary

Beta	0.95
Fifty Two Week Low	$9.57
Fifty Two Week High	$30.41
Fifty Two Week Change	-52.29%
Day 50 MA	$15.29
Day 200 MA	$17.85

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2011-11-17